Previous 10 | Next 10 |
Revenue totals $320.3 million Core Revenue excluding COVID-19 NGS testing grows 59% year-over-year to $25.1 million Raises full year revenue outlook to $660 million from previously announced $600 million Raises full year core revenue outlook to $180 million from previously...
New oncology laboratory will focus on pathology and molecular services, particularly next generation sequencing Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testi...
Fulgent Genetics (NASDAQ:FLGT) Q1 consensus EPS estimate is $3.86 (-41.4% Y/Y) and consensus revenue estimate is $300.5M (-16.4% Y/Y). FLGT is scheduled to announce Q1 earnings results tomorrow, May 3, after market close. Over the last 2 years, FLGT has beaten EPS estimates 75%...
ABNB, ACHC, ADC, AHT, AIG, AIZ, AKAM, ALR, AMCR, AMD, ANDE, APPH, AQST, ATEN, AYX, BFAM, BGFV, BLKB, BNFT, BNL, BTG, BXC, CGBD, CHCT, CNDT, CNR, COKE, CRK, CRUS, CTSO, CWH, CZR, DENN, DHC, DMTK, EGY, EHTH, EIX, ENLC, ENVA, EQX, EXR, FLGT, FPI, FRSH, GLAD, GLRE, GNW, GPOR, GRBK, HASI, HLF, HRZ...
Investing in a growth stock can be risky if the catalyst behind its strong numbers disappears. Over the past couple of years, COVID-19 has led to some strong results for certain companies while others have faltered as a result of the pandemic. A stock that did well due to the pandemic w...
AVISTA CAPITAL PARTNERS COMPLETES SALE OF INFORM DIAGNOSTICS TO FULGENT GENETICS, INC. PR Newswire NEW YORK , April 27, 2022 /PRNewswire/ -- Avista Capital Partners ("Avista"), a leading private equity firm focused exclusively on healthcare, today announc...
Genetic testing company Fulgent Genetics (NASDAQ: FLGT) has had a wild ride over the past few years. At the beginning of the pandemic, Fulgent experienced parabolic revenue growth when it was able to pivot from its core, next-generation sequencing (NGS) business to produce COVID...
Fulgent Genetics (NASDAQ:FLGT) to acquire Inform Diagnostics, a national independent pathology laboratory based in Irving, Texas, and a portfolio company of Avista Capital Partners. Total purchase price of ~$170M, closing expected in Q2. For Q1, anticipates total revenue to be ~$300...
Proposed acquisition will add diagnostic offerings, including hematopathology and anatomic pathology, while also providing a highly complementary nationwide commercial infrastructure to support Fulgent’s rapidly expanding genomic testing footprint Preliminary first quar...
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will relea...
News, Short Squeeze, Breakout and More Instantly...
Fulgent Genetics Inc. Company Name:
FLGT Stock Symbol:
NASDAQ Market:
Fulgent Genetics Inc. Website:
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2024 financial results be...
2024-07-01 14:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 15:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...